Kornimate/medical-research-clean huggingface dataset:
impact of low protein diet supplemented with ketoanalogues supplementation on uremic toxins production

Conditions: Renal Failure

Summary: chronic kidney disease (ckd) is associated with accumulation of uremic toxins like p-cresyl sulfate and indoxyl sulfate that are associated of cardiovascular complication and perturbation of glucose metabolism. these toxins are produced by fermentation of protein by intestinal microbiota but the role of low protein diet and ketoanalogue supplementation on uremic toxins production and microbiota composition are unknown. low protein diet supplemented with ketoanalogues is recommended inckd patients to prevent progression of renal disease. the aim of this study is to determine the impact of uremic toxins concentration, microbiota composition and gut hormone involved in carbohydrate metabolism ( glp-1, fgf19, bile acids) with low protein diet supplemented with ketoanalogues.


Eligibility criteria:
inclusion criteria: * ckd stage 4-5 with estimated glomerular filtration rate \< 30 ml/min/1,73m2 * no dialysis * no history of kidney transplantation * non-diabetic (fasting glucose \<1.26 g / l, or no insulin or oral antidiabetic therapy) * bmi between 18 and 30 kg / m2 * patient followed in the nephrology department of professor fouque at the lyon sud hospital * for women of childbearing age, at least one method of contraception recognized as effective * patient who gave consent to open participation and signed the consent to participate in the study exclusion criteria: * patient with progressive inflammatory, infectious, cardiovascular or neoplastic disease * patient refusing a dietary follow-up * patient having a planned transplant or dialysis project in the next 6 months. * patient having a colectomy, resection of the small intestine or cholecystectomy * patient who has received antibiotics, prebiotics, probiotics in the last 3 months. * patient treated with more than 2 g of calcium per day * patient using laxatives (more than 2 per day) * patient having: * uncontrolled metabolic acidosis (bicarbonatemia \<18 mm) * hyperparathyroidism (pth greater than 5 times the upper limit of normal) * hypercalcemia (calcium\> 2.55 mmol / l) or hypophosphoremia \<0.70 mmol / l * anemia (hemoglobinemia \<80g / l) * undernutrition criteria: albumin \<38 g / l or prealbumin \<0.3 g / l * known hypersensitivity to any of the substances or excipients of ketosteril * subject in exclusion period of a previous study * patient not affiliated to social security * patient under guardianship or in the interests of justice * patient who is pregnant, breastfeeding or likely to become pregnant during the study
efficacy of ac-150 for the treatment of allergic conjunctivitis in the enviro-cac™ model

Conditions: Allergic Conjunctivitis

Summary: the purpose of this study is to evaluate the efficacy of ac-150 compared to vehicle and its components in the prevention of the signs and symptoms of allergic conjunctivitis in enviro-cac™ model.


Eligibility criteria:
inclusion criteria: * positive bilateral conjunctival allergen challenge(cac) reaction exclusion criteria: * known contraindications or sensitivities to the study medication or its components. * any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters. * use of disallowed medications during the period indicated prior to study enrollment or during the study.
parenteral nutrition with intravenous and oral fish oil for intensive care patients

Conditions: Critical Illness

Summary: the primary objective is to assess the effect of fish oil-enriched enteral and parenteral nutrition on blood oxygenation in critically ill patients.


Eligibility criteria:
inclusion: - signed informed consent * mechanically-ventilated adults (age 18-80) admitted to intensive care unit, * enteral nutrition does not meet the nutrition goal (at least 80 % of the resting energy expenditure) within the past 36 hours * apache ii score above the median value of the intensive care unit (id est \> 20) exclusion: - do not resuscitate status * cardiogenic pulmonary edema * previous (\ 0.1 mg/kg prednisolon- equi-valent or other immune suppressive treatment * serum triglycerides \> 300 mg/dl at screening * alterations of coagulation (platelets \ 60 sec, inr ≥ 2.5 without therapeutic intervention * pregnancy * participation in a clinical study with an investigational drug within one month prior to the start of this clinical trial * known or suspected drug abuse * general contraindications for infusion therapy such as acute pulmonary oedema, hyper-hydration and decompensated cardiac insufficiency * known hypersensitivity to egg-, soy-, and fish proteins or any of the ingredients * autoimmune disease or hiv * uncompensated hemodynamical failure of any origin (hemorrhagic shock, myocardial infarction, cardiac failure) * uncompensated ketoacidosis caused by diabetes mellitus within 7 days prior to onset of study * uncompensated renal insufficiency with serum creatinine \> 1.5 mg/dl (\> 133 µmol/l) * patients with severe liver dysfunction with bilirubin \> 2.5 mg/dl (\> 43 µmol/l) * necrotizing pancreatitis

Keywords: critically ill, mechanically ventilated patients requiring enteral and parenteral nutritional support
evaluation of the fim - a non invasive device for temporarily and quick pupil dilation (mydriasis)

Conditions: Pupil Dilation

Summary: the objective of this clinical trial is to evaluate the fim optimal configuration and confirm the safety and performance/efficacy of the fim when exposed to a larger and more varied population of users.

70 eligible subjects will be enrolled to the study and examined with the fim to determine the degree of pupil dilation/contraction resistance. the study will be conducted in two main stages: 1) pupil dilation measuring and 2) functional examination. the tests' sequence will be randomized, at least 30 minutes between each test.

Eligibility criteria:
inclusion criteria: * healthy and not diagnosed with any chronic disease that might influence the eye and pupilary muscle. * age 18-45 years old. * willing and able to sign the informed consent, after reading the study information form exclusion criteria: * any known or diagnosed neurological disorders. * a known medical history of ophthalmic surgery or any other disease that might influence the iris control muscle. * volunteers with a narrow or closed angle of the anterior chamber * presence of a corneal pathology which precludes measurement of the pupil dilatation * using of psychiatric medications * pregnancy * recent use (last 48hr) of pupil dilator eye drops. * the volunteer is participating in other trials using drugs or devices * drug or alcohol abuse

Keywords: field induced mydriasis fim ati
comprehensive management of high-risk population of stroke based on social network

Conditions: Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Summary: the purpose of this study is to evaluate the effectiveness of social network in improving drug compliance and risk factors control rate of stroke high-risk population after discharge.

stroke is the leading cause of death among residents in china, with the characteristics of high morbidity, high mortality, high disability rate, high recurrence rate and so on, which brings huge economic burden to the patients' families and society. strengthening the comprehensive management of the high-risk population of stroke, improving the medication compliance of patients and the control rate of stroke risk factors play a key role in reducing stroke recurrence. this study is a multicenter, prospective, randomized, single-blind study, which aims to use the tool of wechat mini programs to realize the post-hospital follow-up management of the high-risk population of stroke. the follow-up time is 12 months. the main measurement result was the change of patients' medication compliance after comprehensive management.

Eligibility criteria:
inclusion criteria: * age ≥18 years * high-risk population of stroke for hospitalization * modified rankin scale score≤ 2 * patients or primary caregiver have smart phone and wechat accounts * patients take at least one drug for a long time (antihypertensive, hypoglycemic, lipid-lowering, anticoagulant, antiplatelet drugs) * written informed consent exclusion criteria: * patients and their families are unable to operate smartphones * having other diseases that interfere with clinical follow-up assessment (such as cancer, dementia, severe mental illness, etc.) * life expectancy is less than 12 months * patients living in the absence of network conditions

Keywords: stroke management social networks
a study of ustekinumab in pediatric participants with moderately to severely active ulcerative colitis (uc)

Conditions: Colitis, Ulcerative

Summary: the purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics \[pk\]) in pediatric participants with moderately to severely active uc.


Eligibility criteria:
inclusion criteria: * medically stable on the basis of physical examination, medical history, and vital signs, performed at screening. any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and acknowledged by the investigator * must have had uc diagnosed prior to screening * have moderately to severely active uc, defined as a baseline mayo score of 6 through 12, inclusive, with a screening mayo endoscopy subscore greater than or equal to (\>=) 2 as determined by a central review of the video of the endoscopy * a participant who has had extensive colitis for \>= 8 years, or disease limited to the left side of the colon for \>= 10 years, must: a) have had a full colonoscopy to assess for the presence of dysplasia within 1 year before the first administration of study intervention or b) have a full colonoscopy with surveillance for dysplasia as the baseline endoscopy during the screening period. results from these surveillance biopsies must be negative for dysplasia (low-grade, high-grade, or indeterminant) prior to the first administration of study intervention * females of childbearing potential must have a negative highly sensitive urine pregnancy test at screening and at week i-0 prior to study intervention administration exclusion criteria: * have uc limited to the rectum only or to less than (\<) 20 centimeter (cm) of the colon * presence or history of colonic or small bowel obstruction within 6 months prior to screening, confirmed by objective radiographic or endoscopic evidence of a stricture with resulting obstruction (dilation of the colon or small bowel proximal to the stricture on barium radiograph or an inability to traverse the stricture at endoscopy) * have a history of latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis, or have had a nontuberculous mycobacterial infection prior to screening * presence or history of any malignancy including presence or history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (example, nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic areas) and monoclonal gammopathy of undetermined significance, or clinically significant hepatomegaly or splenomegaly * has known allergies, hypersensitivity, or intolerance to ustekinumab or its excipients
acupuncture in menopause

Conditions: Vasomotor Symptoms

Summary: the primary purpose of this study is to determine the effectiveness of acupuncture for treating vasomotor and other symptoms associated with menopause as acupuncture is generally practiced in the "real world" setting and to obtain a comprehensive assessment of use patterns and symptom relief over time. this study will allow us to determine treatment patterns recommended by practicing acupuncturists, adherence to these treatments, and the effectiveness of different treatment patterns for reducing hot flashes. results of this study will provide meaningful information to women in terms of number and frequency of acupuncture treatments likely to be needed to reduce hot flashes.


Eligibility criteria:
inclusion criteria: * women experiencing on average 4 hot flashes a day * women aged 45-60 * peri or post menopausal women (no periods for at least 3 months) exclusion criteria: * women who have initiated cam or non-cam treatments for hot flashes in the last 4 weeks * women who have changed their dose of a cam or non-cam treatments for hot flashes in the last 4 weeks * women who have initiated antidepressants in the last 3 months * women who have changed their dose of an antidepressant in the last 3 months * women who have had acupuncture in the last 4 weeks * women who have received acupuncture from one of the study acupuncturists in the last 6 months will be excluded from the study * women who describe their health as fair or poor are excluded from the study * women who have a diagnosis of hemophilia * relatives and co-workers of the treating acupuncturists

Keywords: acupuncture hot flashes menopause vasomotor symptoms
patient-driven lifestyle modification using freestyle libre in type 2 diabetes patients

Conditions: Diabetes Mellitus, Type 2; Lifestyle Risk Reduction

Summary: we aim to provide medical nutritional therapy to patients with type 2 diabetes who are on oral hypoglycemic agents or on basal insulin only and monitor the glycemic response with flash glucose monitoring or self-monitoring of blood glucose. specifically, this is a randomized, open-label, controlled study where half of the study participants will have freestyle libre device on for 12 weeks and compare the change in glycated hemoglobin (hba1c) value with the patients in the control group.

subjects: 126 patients with type 2 diabetes mellitus scheme: multi-center, randomized, open-label, controlled study this study is referred to as the "patient-driven lifestyle modification using freestyle libre in type 2 diabetes patients", also known as the pdf study. it will assess potential benefits of using continuous glucose monitoring (cgm) versus self monitoring of blood glucose (smbg) when combined with personalized education on lifestyle modification in people with type 2 diabetes. specifically, we will investigate patients who have an elevated hba1c between 7.0 - 10.0% who are not using prandial insulin. potential participants will be screened from routine outpatient clinic visits, will be randomized to either the cgm or smbg group in a 1:1 ratio. participants from both groups will receive education on lifestyle modification and will be reminded every 4 weeks with structured phone visits. study will be completed at the visit on 12 weeks of follow up with the same laboratory examinations (including hba1c) and survey from the baseline.

Eligibility criteria:
inclusion criteria: * age 19-80 * diagnosed with type 2 diabetes mellitus (dm) * uncontrolled type 2 dm: hba1c 7.0-10.0% * signed informed consent exclusion criteria: * diagnosed with other types of diabetes mellitus (i.e. type 1 dm) * use of prandial insulin * change in diabetes medication in the preceding 3 months * pregnant/lactating women * addiction to drugs and alcohol * use of medications that result in drug-induced hyperglycemia (i.e. steroid) * severe liver disease * end-stage renal disease (i.e. on dialysis) * unable to wear cgm devices due to dermatologic side effects (i.e. severe burn, inflammation, active skin infection, severe skin reactions, hypertrichosis, etc.) * conditions that impact the stability of hba1c measurement
electrical brain stimulation for treatment of secondary symptoms in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is an autoimmune disease associated with physical disability, psychological impairment, and cognitive dysfunction. as a result, the disease burden is high, and treatment options are limited. in this randomized, double-blind study, the investigators planned to use repeated electrical stimulation and assess mental health-related variables (e.g., quality of life, sleep, psychological distress) and cognitive dysfunction in patients with ms.


Eligibility criteria:
inclusion criteria: 1. diagnosis of ms according to the diagnostic criteria for multiple sclerosis: 2010 revisions to the mcdonald criteria (polman et al., 2011), certified by a professional neurologist 2. being 25-55 years old 3. providing written informed consent 4. if female, a negative urine pregnancy test 5. stable medication regime especially the classical neuroleptics and all cns-activating medications, if taken, 4-6 weeks before the experiment and during the experiment 6. right handed exclusion criteria: 1. smoker 2. pregnancy 3. alcohol or substance dependence 4. history of seizure 5. history of other neurological disorders than ms 6. history of head injury 7. presence of ferromagnetic objects in the body that are contraindicated for brain stimulation of the head (pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments) or fear of enclosed spaces.
autoimmunity in inner ear disease

Conditions: Hearing Loss, Sensorineural

Summary: the purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive sensorineural hearing loss in both ears. this condition is called autoimmune inner ear disease (aied), because it is thought that the hearing loss is triggered by an autoimmune process. treatment attempts to suppress or control this process with powerful anti-inflammatory drugs. this is a phase iii, outpatient study. all study participants will be assigned to one of four different groups testing the experimental use of drugs. the study is scheduled to run for 18 months, with a minimum of 11 visits per participant.


Eligibility criteria:
inclusion criteria: * have sensorineural (nerve/inner ear) hearing loss of at least 30 db in each ear, which has rapidly progressed. * are in good general health. * are sterile or use contraception (if a woman of child-bearing age). * are able to speak and understand english or spanish. exclusion criteria: * have had any previous reaction to prednisone, or history of psychiatric reaction to corticosteroids. * have used corticosteroids for more than 30 days within the past 90 days. patients who have been off corticosteroids for at least 30 days may be eligible. * have any significant heart, lung, digestive, blood, or neurologic disorders. * have tuberculosis (tb), brittle or unstable insulin-dependent diabetes mellitus, active malignancy or prior chemotherapy, pancreatitis, active peptic ulcer disease, kidney failure, history of shingles, or known (other) autoimmune disease. * have had a positive test for hiv, hepatitis c or b. * have any type of middle ear disorder. * are breast-feeding or pregnant.

Keywords: autoimmune diseases cyclophosphamide hearing labyrinth diseases methotrexate prednisone
the use of growing rods in pediatric long bones deformity correction

Conditions: Deformity of Limb

Summary: the objective of this study is to evaluate the value of growing rods for the correction of long bone deformities in pediatric cases attending sohag university hospital and follow up aiming at determining benefits and obstacles to this technique

* the participants will be subjected to surgical correction using growing rods as a novel technique for their long bone deformities. * procedure will be done under anaesethia * osteotomy , fracture reduction , deformity correction will be done , then introduction of the growing rod

Eligibility criteria:
inclusion criteria: * cases of osteogenesis imperfecta * metabolic bone deformities * cases of hemimelia * traumatic bone deformities * complex or simple deformities exclusion criteria: * adult deformities * short bone deformities * very narrow medulla * osteopetrosis
effect of specific immunotherapy to dust mites in children with asthma

Conditions: Asthma

Summary: the aim of the study is to assess the effect of specific immunotherapy (sit) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, chosen markers of inflammation, induction of regulatory lymphocytes, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of sit in children with asthma.

specific immunotherapy is the only one causal treatment method of atopic diseases including bronchial asthma in children. the aim of the study is to assess the effect of specific immunotherapy (sit) to dust mites on clinical symptoms,reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, chosen markers of inflammation, induction of regulatory lymphocytes, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of sit in children with asthma.

Eligibility criteria:
inclusion criteria: * patients allergic to house dust mites * patients with moderate bronchial asthma * patients with controlled asthma * patients who were qualified for immunotherapy and gave written informed consent for immunotherapy (active treatment group) * patients who were qualified for immunotherapy and did not agree with this kind of treatment - did not give written informed consent for immunotherapy (control group) exclusion criteria: * patients allergic for other perennial and seasonal allergens * patients with other chronic diseases that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator * medications that resulted in patient exclusion included:anti-parasites or oral corticosteroids within 6 months before the first visit.

Keywords: asthma immunotherapy children regulatory t cells ecp pc20m quality of life symptoms score spirometry